Immune Response of A Novel ATR-AP205-001 Conjugate Anti-hypertensive Vaccine
Abstract We developed a virus-like particle (VLP)-based therapeutic vaccine against angiotensin II receptor type 1, ATR-AP205-001, which could significantly reduce the blood pressure and protect target organs of hypertensive animals. In this study, we focused on the immunological effect and safety o...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/462bb5a5eafc4ab8b2d68050165b2407 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:462bb5a5eafc4ab8b2d68050165b2407 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:462bb5a5eafc4ab8b2d68050165b24072021-12-02T15:05:50ZImmune Response of A Novel ATR-AP205-001 Conjugate Anti-hypertensive Vaccine10.1038/s41598-017-12996-y2045-2322https://doaj.org/article/462bb5a5eafc4ab8b2d68050165b24072017-10-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-12996-yhttps://doaj.org/toc/2045-2322Abstract We developed a virus-like particle (VLP)-based therapeutic vaccine against angiotensin II receptor type 1, ATR-AP205-001, which could significantly reduce the blood pressure and protect target organs of hypertensive animals. In this study, we focused on the immunological effect and safety of the VLP-based vaccine. By comparing to the depolymerized dimeric vaccine ATR-Dimer-001, we found that ATR-AP205-001 reached subcapsular sinus of lymph node shortly after administration, followed by accumulation on follicle dendritic cells via follicle B cell transportation, while ATR-Dimer-001 vaccine showed no association with FDCs. ATR-AP205-001 vaccine strongly activated dendritic cells, which promoted T cells differentiation to follicular helper T cells. ATR-AP205-001 vaccine induced powerful germinal center reaction, which was translated to a boost of specific antibody production and long-lasting B cell memory, far superior to ATR-Dimer-001 vaccine. Moreover, neither cytotoxic T cells, nor Th1/Th17 cell-mediated inflammation was observed in ATR-AP205-001 vaccine, similar to ATR-Dimer-001 vaccine. We concluded that ATR-AP205-001 vaccine quickly induced potent humoral immunity through collaboration of B cells, follicular dendritic cells and follicular helper T cells, providing an effective and safe intervention for hypertension in the future clinical application.Xiajun HuYihuan DengXiao ChenYanzhao ZhouHongrong ZhangHailang WuShijun YangFen ChenZihua ZhouMin WangZhihua QiuYuhua LiaoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-13 (2017) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Xiajun Hu Yihuan Deng Xiao Chen Yanzhao Zhou Hongrong Zhang Hailang Wu Shijun Yang Fen Chen Zihua Zhou Min Wang Zhihua Qiu Yuhua Liao Immune Response of A Novel ATR-AP205-001 Conjugate Anti-hypertensive Vaccine |
| description |
Abstract We developed a virus-like particle (VLP)-based therapeutic vaccine against angiotensin II receptor type 1, ATR-AP205-001, which could significantly reduce the blood pressure and protect target organs of hypertensive animals. In this study, we focused on the immunological effect and safety of the VLP-based vaccine. By comparing to the depolymerized dimeric vaccine ATR-Dimer-001, we found that ATR-AP205-001 reached subcapsular sinus of lymph node shortly after administration, followed by accumulation on follicle dendritic cells via follicle B cell transportation, while ATR-Dimer-001 vaccine showed no association with FDCs. ATR-AP205-001 vaccine strongly activated dendritic cells, which promoted T cells differentiation to follicular helper T cells. ATR-AP205-001 vaccine induced powerful germinal center reaction, which was translated to a boost of specific antibody production and long-lasting B cell memory, far superior to ATR-Dimer-001 vaccine. Moreover, neither cytotoxic T cells, nor Th1/Th17 cell-mediated inflammation was observed in ATR-AP205-001 vaccine, similar to ATR-Dimer-001 vaccine. We concluded that ATR-AP205-001 vaccine quickly induced potent humoral immunity through collaboration of B cells, follicular dendritic cells and follicular helper T cells, providing an effective and safe intervention for hypertension in the future clinical application. |
| format |
article |
| author |
Xiajun Hu Yihuan Deng Xiao Chen Yanzhao Zhou Hongrong Zhang Hailang Wu Shijun Yang Fen Chen Zihua Zhou Min Wang Zhihua Qiu Yuhua Liao |
| author_facet |
Xiajun Hu Yihuan Deng Xiao Chen Yanzhao Zhou Hongrong Zhang Hailang Wu Shijun Yang Fen Chen Zihua Zhou Min Wang Zhihua Qiu Yuhua Liao |
| author_sort |
Xiajun Hu |
| title |
Immune Response of A Novel ATR-AP205-001 Conjugate Anti-hypertensive Vaccine |
| title_short |
Immune Response of A Novel ATR-AP205-001 Conjugate Anti-hypertensive Vaccine |
| title_full |
Immune Response of A Novel ATR-AP205-001 Conjugate Anti-hypertensive Vaccine |
| title_fullStr |
Immune Response of A Novel ATR-AP205-001 Conjugate Anti-hypertensive Vaccine |
| title_full_unstemmed |
Immune Response of A Novel ATR-AP205-001 Conjugate Anti-hypertensive Vaccine |
| title_sort |
immune response of a novel atr-ap205-001 conjugate anti-hypertensive vaccine |
| publisher |
Nature Portfolio |
| publishDate |
2017 |
| url |
https://doaj.org/article/462bb5a5eafc4ab8b2d68050165b2407 |
| work_keys_str_mv |
AT xiajunhu immuneresponseofanovelatrap205001conjugateantihypertensivevaccine AT yihuandeng immuneresponseofanovelatrap205001conjugateantihypertensivevaccine AT xiaochen immuneresponseofanovelatrap205001conjugateantihypertensivevaccine AT yanzhaozhou immuneresponseofanovelatrap205001conjugateantihypertensivevaccine AT hongrongzhang immuneresponseofanovelatrap205001conjugateantihypertensivevaccine AT hailangwu immuneresponseofanovelatrap205001conjugateantihypertensivevaccine AT shijunyang immuneresponseofanovelatrap205001conjugateantihypertensivevaccine AT fenchen immuneresponseofanovelatrap205001conjugateantihypertensivevaccine AT zihuazhou immuneresponseofanovelatrap205001conjugateantihypertensivevaccine AT minwang immuneresponseofanovelatrap205001conjugateantihypertensivevaccine AT zhihuaqiu immuneresponseofanovelatrap205001conjugateantihypertensivevaccine AT yuhualiao immuneresponseofanovelatrap205001conjugateantihypertensivevaccine |
| _version_ |
1718388700600074240 |